MannKind's ReadyFlow Launch Keeps The Bull Case Alive
MannKind Corporation 2026 Q3 - Results - Earnings Call Presentation
MannKind to Participate in Upcoming Investor Conferences
MannKind (MNKD) Q3 2026 Earnings Call Transcript
RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5
MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ...
Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results?
Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10
MannKind Q3 Earnings Call Highlights
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
MannKind: Q3 Earnings Snapshot
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
Can MannKind (MNKD) Still Be A Bargain On Cash Flow?
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data
Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.